Get the Stockscreener App
1.82
1.09%
-0.02
Minerva Neurosciences Inc stock is traded at $1.82, with a volume of 27,676.
It is down -1.09% in the last 24 hours and down -16.70% over the past month.
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
See More
Previous Close:
$1.84
Open:
$1.84
24h Volume:
27,676
Relative Volume:
0.68
Market Cap:
$12.73M
Revenue:
-
Net Income/Loss:
$-33.65M
P/E Ratio:
-0.409
EPS:
-4.45
Net Cash Flow:
$-20.83M
1W Performance:
-7.61%
1M Performance:
-16.70%
6M Performance:
-31.58%
1Y Performance:
-79.32%
1-Day Range:
$1.81
$1.9125
1-Week Range:
$1.77
$2.05
52-Week Range:
$1.77
$9.40
Minerva Neurosciences Inc Stock (NERV) Company Profile
Name
Minerva Neurosciences Inc
Sector
Industry
Phone
617-600-7373
Address
1601 TRAPELO ROAD, WALTHAM, MA
Compare NERV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NERV
Minerva Neurosciences Inc
|
1.82 | 12.73M | 0 | -33.65M | -20.83M | -4.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Minerva Neurosciences Inc Stock (NERV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-08-20 | Reiterated | H.C. Wainwright | Buy |
| May-14-20 | Initiated | BTIG Research | Buy |
| Oct-02-19 | Reiterated | Chardan Capital Markets | Buy |
| Sep-25-19 | Initiated | Chardan Capital Markets | Buy |
| Sep-18-19 | Initiated | William Blair | Outperform |
| May-31-19 | Initiated | H.C. Wainwright | Buy |
| Sep-01-17 | Initiated | Citigroup | Buy |
| Mar-06-17 | Resumed | Jefferies | Buy |
| May-12-16 | Resumed | Jefferies | Buy |
View All
Minerva Neurosciences Inc Stock (NERV) Latest News
Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated at StockNews.com - Defense World
Minerva Neurosciences (NERV) Expected to Announce Quarterly Earnings on Thursday - Defense World
Minerva Neurosciences stock hits 52-week low at $1.86 - Investing.com India
Minerva Neurosciences stock hits 52-week low at $1.86 By Investing.com - Investing.com Nigeria
Minerva Neurosciences Inc expected to post a loss of $1.05 a shareEarnings Preview - TradingView
Minerva Neurosciences Stock Hits 52-Week Low at $2.03 - MSN
Minerva Neurosciences (NASDAQ:NERV) Earns Sell Rating from Analysts at StockNews.com - Defense World
Minerva Neurosciences stock hits 52-week low at $2.02 By Investing.com - Investing.com Nigeria
Minerva Neurosciences stock hits 52-week low at $2.02 - Investing.com
Minerva Neurosciences (NASDAQ:NERV) Now Covered by Analysts at StockNews.com - Armenian Reporter
GHP Investment Advisors Inc. Reduces Stock Holdings in Silgan Holdings Inc. (NYSE:SLGN) - Armenian Reporter
Mohawk Industries (NYSE:MHK) Issues Quarterly Earnings Results - Armenian Reporter
Promising Penny Stocks To Follow Today – February 04th - Armenian Reporter
Chronic Insomnia Market Outlook: Strong Growth Projected by 2032, Highlights DelveInsight - NEWSnet
Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated by Analysts at StockNews.com - Defense World
Investor Network: Minerva Neurosciences Inc to Host Earnings Call - ACCESS Newswire
StockNews.com Begins Coverage on Minerva Neurosciences (NASDAQ:NERV) - Defense World
Minerva Neurosciences (NASDAQ:NERV) vs. SciSparc (NASDAQ:SPRC) Financial Contrast - Defense World
Minerva Neurosciences Faces Listing Compliance Challenges as Nasdaq Grants Continued Listing Subject to ConditionsMinerva Neurosciences Inc. recently encountered challenges regarding its listing on The Nasdaq Capital Market as disclosed in a Form 8 - Defense World
Minerva Neurosciences secures Nasdaq listing extension By Investing.com - Investing.com South Africa
Minerva Neurosciences secures Nasdaq listing extension - Investing.com
StockNews.com Initiates Coverage on Minerva Neurosciences (NASDAQ:NERV) - Defense World
Minerva Neurosciences (NASDAQ:NERV) Now Covered by StockNews.com - Defense World
Future Industry Growth Of Cognitive Behavioral Therapy - openPR
Neurological stocks rise and fall on clinical data; index down - BioWorld Online
Minerva Neurosciences reports voting results from annual meeting By Investing.com - Investing.com Nigeria
Minerva Neurosciences stock hits 52-week low at $2.07 - Investing.com India
Minerva Neurosciences stock hits 52-week low at $2.07 By Investing.com - Investing.com UK
Minerva Neurosciences reports voting results from annual meeting - Investing.com
Minerva Neurosciences : ROSEN, RECOGNIZED INVESTOR COUNSEL, Reminds Minerva Neurosciences, Inc. Investors of Important Deadline in Securities Class ActionNERV - Marketscreener.com
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.25% - MSN
Reviewing Vistagen Therapeutics (NASDAQ:VTGN) and Minerva Neurosciences (NASDAQ:NERV) - Defense World
500: Something went wrong - Investing.com
Minerva Neurosciences stock hits 52-week low at $2.25 By Investing.com - Investing.com Canada
Minerva Neurosciences’ (NERV) “Neutral” Rating Reiterated at HC Wainwright - Defense World
Minerva Neurosciences Reports Positive Earnings Amid FDA Challenges - TipRanks
Minerva Neurosciences: Q3 Earnings Snapshot - San Francisco Chronicle
Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates - GlobeNewswire
Minerva Neurosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Major Depressive Disorder Market Expected to Experience Major Growth by 2034, According to DelveInsight | Takeda, Otsuka Pharma, AbbVie, SAGE Therapeutics, Forest Laboratories, Axsome Therapeutics - The Globe and Mail
Minerva Neurosciences Inc Stock (NERV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):